Safety and efficacy of azacitidine in myelodysplastic syndromes

PURPOSE: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigil, Carlos E, Martin-Santos, Taida, Garcia-Manero, Guillermo
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948932/
https://www.ncbi.nlm.nih.gov/pubmed/20957213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948932/
https://www.ncbi.nlm.nih.gov/pubmed/20957213

Ejemplares similares